Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- InSite Vision Inc. Q4 2008 Earnings Call Transcript
- Question-and-Answer Session Unidentified Analyst What is the status of the CEO search? Louis Drapeau As many of you know, we've engaged an executive recruitment firm that's been conducting an active search. We've had a lot of interest in the position and identified several exceptional candidates. In order...
- Earnings calls 2009-03-04
Additional Resources
- InSite Vision Meets with the FDA on Pre-NDA Discussions for AzaSite
- ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug-delivery company -- today announced a pre-NDA meeting with representatives of the U.S. Food and Drug Administration FDA was held on Tuesday, June 21, 2005. The purpose of the meeting was to discuss sections of the proposed...
- Research articles 2005-06-22
- InSite Vision Meets With the FDA on Pre-NDA Discussions for AzaSite™
- ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug-delivery company -- today announced that it had a pre-NDA meeting with representatives of the U.S. Food and Drug Administration FDA on Wednesday, April 26, 2006. The purpose of the meeting was to discuss the proposed new...
- Research articles 2006-04-27
- InSite Vision Announces Positive Top-Line Results from First of Two Pivotal Phase 3 Clinical Trials; Pivotal Trial Succeeds in Reaching Primary Efficacy Endpoint of Clinical Resolution
- ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV) today announced positive top-line results from a pivotal phase 3 clinical trial of AzaSiteTM, a sterile, topical ophthalmic anti-infective solution containing 1.0% azithromycin formulated in DuraSiteR (the Company's patented drug delivery system). In an international, controlled clinical trial, subjects with bacterial conjunctivitis (pink-eye)...
- Research articles 2005-11-30
- InSite Vision Announces FDA Acceptance of New Drug Application for Review
- ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug delivery company, today announced the U.S. Food and Drug Administration has accepted for filing and comprehensive review, InSite Vision's NDA for AzaSite (azithromycin 1% ophthalmic solution), indicated for the treatment of bacterial conjunctivitis. AzaSite is formulated...
- Research articles 2006-08-28
- InSite Vision to Present Results From Second of Two Pivotal Phase 3 Clinical Trials
- ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV), an ophthalmic company focused on ocular infections, glaucoma and retinal diseases, announced today the acceptance of two abstracts related to its second pivotal trial of the topical eye drop antibiotic, AzaSite (1% azithromycin in DuraSiteR). The vehicle-controlled, prospective, multi-center, bacterial conjunctivitis trial showed...
- Research articles 2006-08-03
- InSite Vision Inc. Wall Street Analyst Forum Presentation Transcript
- Earnings Call ExcerptInSite Vision Inc. ISV Wall Street Analyst Forum September 10, 2008 2:00 pm ET Executives S. Kumar Chandrasekaran - Chairman, President and CEO Presentation Moderator Good afternoon, ladies and gentlemen. I like to introduce the next company in this afternoon’s biotechnology and specialty pharmaceutical program. I...
- Earnings calls 2008-09-10
- Inspire Pharmaceuticals, Q2 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Joseph Schwartz with Leerink Swann. Joseph Schwartz - Leerink Swann Hi. Good morning. Congratulations on all the progress. I was wondering, first on denufosol, did you actually hold a meeting with the FDA and discuss whether the...
- Earnings calls 2008-08-11
- Inspire Pharmaceuticals Q4 2007 Earnings Call Transcript
- Question-and-Answer Session Operator Your first question comes from Liana Moussatos - Pacific Growth. Liana Moussatos - Pacific Growth When you release the TIGER-1 data, is there any chance that it’s going to happen at ATS or will you have any data at ATS? Christy L. Shaffer We actually expect...
- Earnings calls 2008-02-27
- Inspire Pharmaceuticals, Inc. F4Q and Full Year 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from Liana Moussatos of Wedbush Morgan. Liana Moussatos - Wedbush Morgan Could you repeat the quarter-over-quarter AzaSite sales and prescription growth and then what was the stock based compensation amount? Also, how many potential partners are in discussion...
- Earnings calls 2009-03-03
- InSite Vision to Hold Conference Call to Discuss Top Line Results of Pivotal Phase 3 Clinical Trial on November 30th
- ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV), an ophthalmic therapeutics, diagnostics and drug-delivery company, announced today that the Company will hold a conference call to discuss the top line results of one of its two pivotal phase 3 clinical trials of AzaSite, azithromycin 1% solution in DuraSiteR, on Wednesday, November...
- Research articles 2005-11-29
- InSite Vision Announces Patent Agreement With Pfizer
- ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug delivery company, today announced that it has entered into a worldwide, exclusive royalty bearing licensing agreement with Pfizer Inc. (NYSE:PFE) under Pfizer's Patent family titled "Method of Treating Eye Infections with Azithromycin". Pfizer's granting of this...
- Research articles 2007-02-15
- InSite Vision Initiates Pivotal Phase 3 Trials for AzaSite Plus™
- Topical Antibiotic/Corticosteroid to Treat Chronic Eye Inflammation and Infection
- Research articles 2007-12-20
- Inspire Provides 2008 Financial Guidance
- DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today revenue and expense guidance for the full year of 2008. Inspire expects to record aggregate revenue in the range of $62-$76 million and expects operating expenses to be in the range of $109-$129 million in 2008. Based on current...
- Research articles 2008-01-18
- Inspire Announces Poster Presentation at American Society of Cataract and Refractive Surgery Annual Symposium
- DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists and collaborators will present information in a poster presentation at the American Society of Cataract and Refractive Surgery 2008 Symposium on April 4-9, 2008 in Chicago, IL. The poster, "Comparison of AzaSite([R]) and Azithromycin 1% for...
- Research articles 2008-04-04
- Inspire Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you, sir. Operator instructions Your first question comes from the line of Liana Moussatos with Wedbush. Liana Moussatos – Wedbush Morgan What was the non-cash stock option expense in Q1? Tom Staab Liana, I don’t have that number on my – at my fingertips, but typical...
- Earnings calls 2009-05-08
- << Previous
- page 1 of 1
- Next >>
